Mindera Health™ Announces Coverage with Evidence Project with Highmark, Inc. to Advance Moderate-to-Severe Psoriasis Patient Care and Reduce Specialty Drug Spending
April 11, 2023 09:00 ET
|
Mindera Health
San Diego, CA, April 11, 2023 (GLOBE NEWSWIRE) -- Mindera Health™, the developer of Mind.Px, the first realization of precision medicine in psoriasis, has initiated a coverage with evidence project...
Interim Results of MATCH Study Demonstrate Improved Decision Making and Clinical Outcomes When Using Mind.Px™ to Determine Biologic Drug Class for Psoriasis Patients
October 20, 2022 08:00 ET
|
Mindera Health
San Diego, CA, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Interim clinical utility and patient outcomes data regarding Mindera Health’s Mind.Px™ test from the ongoing MATCH study were recently presented at...